EC approves label update for BMS’ Daklinza
10 September 2015 | By Victoria White
The update allows the use of Daklinza in combination with sofosbuvir for 12 weeks in patients without cirrhosis in all 28 Member States of the European Union...
List view / Grid view
News
Thermo Fisher Scientific receives IVDD CE Mark
Thermo Fisher Scientific, the world leader in serving science, announced that it received the in vitro diagnostics device (IVDD) CE mark for its Thermo Scientific Prelude MD HPLC, Endura MD mass spectrometer and ClinQuan MD software.
Wanted: clever minds!
10 September 2015 | By Shimadzu
‘lab4you’ program for young scientists / Laboratory space available for research / Brief abstract for application...
Janssen submits MAA for daratumumab to EMA
10 September 2015 | By Victoria White
Daratumumab is an investigational, human anti-CD38 monoclonal antibody, for the treatment of patients with relapsed and refractory multiple myeloma...
FDA grants Priority Review to ixazomib for multiple myeloma
10 September 2015 | By Victoria White
Ixazomib is the first investigational oral proteasome inhibitor for the treatment of patients with relapsed and/or refractory multiple myeloma...
Pivotal Phase 3 data on Kanuma in LAL-D published
10 September 2015 | By Victoria White
In the Phase 3 study, Kanuma met the primary endpoint of alanine aminotransferase (ALT) normalisation compared with placebo as well as six secondary endpoints...
Allergic rhinitis treatment market to remain stagnant over next decade
9 September 2015 | By Victoria White
The value of the global treatment market for allergic rhinitis will witness minimal growth from $7.2 billion in 2014 to $7.3 billion by 2024, says research and consulting firm GlobalData...
Further evidence for the potential of AZD9291 in NSCLC presented at WCLC
9 September 2015 | By Victoria White
Data demonstrated that in 60 patients who received AZD9291 once daily in the first-line setting, 72% were progression free at 12 months...
First patient enrolled in Phase 4 AUGUSTUS trial of Eliquis
9 September 2015 | By Victoria White
The trial will evaluate the safety of Eliquis versus warfarin or other vitamin K antagonists in patients with nonvalvular atrial fibrillation and a recent acute coronary syndrome or undergoing percutaneous coronary intervention...
Phase III data confirms efficacy of perampanel and rufinamide
9 September 2015 | By Victoria White
Data presented at the International Epilepsy Congress in Istanbul show Eisai’s perampanel may significantly reduce seizure frequency, both in patients with primary generalised tonic-clonic (PGTC) seizures and partial epilepsy...
Results from the SUMMIT COPD CV survival study announced
9 September 2015 | By Victoria White
For the primary endpoint of the study, the risk of dying on Relvar/Breo Ellipta 100/25mcg was 12.2% lower than on placebo over the study period, which was not statistically significant...
EC grants marketing authorisation for Raxone in Leber’s Hereditary Optic Neuropathy
9 September 2015 | By Victoria White
Raxone is the first approved treatment for Leber’s Hereditary Optic Neuropathy, and for a mitochondrial disease, in the EU...
AstraZeneca in bioinformatics collaboration with University of Manchester
9 September 2015 | By Victoria White
AstraZeneca and The University of Manchester are teaming up to harness clinical bioinformatics to deliver personalised healthcare for cancer patients...
New analytical solution brings nanoscale chemical imaging to new levels of ease and automation.
8 September 2015 | By HORIBA Scientific
HORIBA Scientific, global leader in Raman spectroscopy solutions, announces an innovative solution that addresses the challenges of TERS imaging...
First patient enrolled in Phase 3 study of aducanumab in Alzheimer’s
8 September 2015 | By Victoria White
Biogen's Phase 3 programme includes two global studies designed to evaluate the efficacy and safety of aducanumab in slowing cognitive impairment and the progression of disability in people with early Alzheimer’s disease...
